{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:30Z","timestamp":1792787310204,"version":"4.5.0"},"reference-count":36,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Region Uppsala\/\u00d6sterg\u00f6tland ALF Grants","award":["R\u00d6-981263"],"award-info":[{"award-number":["R\u00d6-981263"]}]},{"name":"Swedish Society for Medical Research","award":["S20-0127"],"award-info":[{"award-number":["S20-0127"]}],"id":[{"id":"https:\/\/ror.org\/0433fd238","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Sigrid Anderssons foundation"},{"name":"Gurli and Edward Brunnberg Foundation"},{"name":"Swedish Society of Medicine-the Ingegerd Johansson donation","id":[{"id":"https:\/\/ror.org\/016ks4x90","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Swedish Research Council for Medicine and Health","award":["2023-02256"],"award-info":[{"award-number":["2023-02256"]}],"id":[{"id":"https:\/\/ror.org\/03zttf063","id-type":"ROR","asserted-by":"crossref"}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["FAI-2022-0877"],"award-info":[{"award-number":["FAI-2022-0877"]}],"id":[{"id":"https:\/\/ror.org\/02szc9j24","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["[2023\u221236]"],"award-info":[{"award-number":["[2023\u221236]"]}]},{"name":"Swedish Kidney Foundation","award":["F2023-0026"],"award-info":[{"award-number":["F2023-0026"]}]},{"name":"Swedish Rheumatism Association","award":["R-993724"],"award-info":[{"award-number":["R-993724"]}],"id":[{"id":"https:\/\/ror.org\/00zps9v98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Agnes och Mac Rudberg Foundation"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2026,8,5]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Lupus nephritis (LN) is a potentially severe manifestation of SLE, often resulting in permanent kidney damage. We investigated whether polygenic and\/or epigenetic risk is associated with time to LN relapse and whether this association differs by initial therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Caucasian patients with biopsy-verified LN between 1974 and 2022 (n=149) were genotyped using the Illumina Global Screening Array, and DNA methylation was assessed with the Illumina HumanMethylation450k BeadChip. A weighted Polygenic Risk Score (PRS) based on 55 non-Human leukocyte antigen (HLA) SLE risk gene variants and a Methylation Risk Score (MRS) based on the 17 most differentially methylated cytosine-phosphate-guanine sites identified in SLE-control comparison were calculated. Time to LN relapse was analysed using Cox proportional hazards models, adjusted for centre, sex and year of the first LN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Neither PRS nor MRS was associated with time to LN relapse in the overall cohort, irrespective of treatment (PRS: HR=1.00 (0.77\u20131.30); p=0.99; MRS: HR=1.01 (1.00\u20131.02); p=0.21). No associations were observed among cyclophosphamide (CYC)-treated patients (PRS: HR=0.81 (0.55\u20131.20); p=0.29; MRS: HR=1.00 (0.99\u20131.02); p=0.89). In non-CYC-treated patients, PRS showed a non-significant trend towards shorter time to LN relapse (HR=1.26 (0.88\u20131.81); p=0.21), with a similar trend for MRS (HR=1.02 (1.00\u20131.03); p=0.066). Adding MRS to the PRS model improved performance in this subgroup (likelihood ratio test, p=0.028), with significant associations for MRS (PRS: HR=1.56 (0.97\u20132.50); p=0.066; MRS: HR=1.02 (1.00\u20131.04); p=0.037).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Genetic and epigenetic susceptibility appears to influence LN relapse risk in a treatment-dependent manner. The absence of an association among patients receiving CYC suggests that initial treatment with CYC may attenuate the impact of genetic and epigenetic predisposition on relapse. These findings support the potential of genetic and epigenetic profiling at LN diagnosis to improve relapse risk stratification and individualise selection of treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2026-002043","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:25:10Z","timestamp":1788261910000},"page":"e002043","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Genetic and epigenetic determinants of relapse risk in lupus nephritis"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4243-9575","authenticated-orcid":false,"given":"Elisabeth","family":"Skoglund","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Skoglund","sequence":"additional","affiliation":[{"name":"Division of Inflammation and Infection\/Rheumatology, Department of Biomedical and Clinical Sciences, Linkoping University, Link\u00f6ping, \u00d6sterg\u00f6tland County, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6622-8897","authenticated-orcid":false,"given":"Holme","family":"Vestin","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3179-1258","authenticated-orcid":false,"given":"Nina","family":"Oparina","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Sayadi","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6753-7107","authenticated-orcid":false,"given":"Francesca","family":"Faustini","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3396-3244","authenticated-orcid":false,"given":"Elisabet","family":"Svenungsson","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9403-6503","authenticated-orcid":false,"given":"Lars","family":"Ronnblom","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7545-5585","authenticated-orcid":false,"given":"Maria K","family":"Svensson","sequence":"additional","affiliation":[{"name":"Dept. of Medical Sciences, Renal Medicine, Uppsala University, Uppsala, Sweden"},{"name":"Uppsala Clinical Research Center, Uppsala, Uppsala County, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7230-8990","authenticated-orcid":false,"given":"Juliana","family":"Imgenberg-Kreuz","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Gunnarsson","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-2048","authenticated-orcid":false,"given":"Christopher","family":"Sj\u00f6wall","sequence":"additional","affiliation":[{"name":"Division of Inflammation and Infection\/Rheumatology, Department of Biomedical and Clinical Sciences, Linkoping University, Link\u00f6ping, \u00d6sterg\u00f6tland County, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6275-7282","authenticated-orcid":false,"given":"Dag","family":"Leonard","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"2026092908102872000_13.2.e002043.1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320932219"},{"key":"2026092908102872000_13.2.e002043.2","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu444oa"},{"key":"2026092908102872000_13.2.e002043.3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026092908102872000_13.2.e002043.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"2026092908102872000_13.2.e002043.5","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/art.43212","article-title":"American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis","volume":"77","author":"Sammaritano","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026092908102872000_13.2.e002043.6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.kint.2023.09.001","article-title":"Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis","volume":"105","author":"Rovin","year":"2024","journal-title":"Kidney Int"},{"key":"2026092908102872000_13.2.e002043.7","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000527"},{"key":"2026092908102872000_13.2.e002043.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160214"},{"key":"2026092908102872000_13.2.e002043.9","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1996.528"},{"key":"2026092908102872000_13.2.e002043.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.108953"},{"key":"2026092908102872000_13.2.e002043.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-021-00900-w"},{"key":"2026092908102872000_13.2.e002043.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41435-021-00142-8"},{"key":"2026092908102872000_13.2.e002043.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084450","article-title":"Association of STAT4 polymorphism with severe renal insufficiency in lupus nephritis","volume":"8","author":"Bolin","year":"2013","journal-title":"PLoS One"},{"key":"2026092908102872000_13.2.e002043.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219727"},{"key":"2026092908102872000_13.2.e002043.15","doi-asserted-by":"crossref","DOI":"10.3389\/flupu.2024.1398035","article-title":"The 330 risk loci known for systemic lupus erythematosus (SLE): a review","volume":"2","author":"Laurynenka","year":"2024","journal-title":"Front Lupus"},{"key":"2026092908102872000_13.2.e002043.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216227"},{"key":"2026092908102872000_13.2.e002043.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212379"},{"key":"2026092908102872000_13.2.e002043.18","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-000926","article-title":"B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus","volume":"10","author":"Hedenstedt","year":"2023","journal-title":"Lupus Sci Med"},{"key":"2026092908102872000_13.2.e002043.19","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu049"},{"key":"2026092908102872000_13.2.e002043.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208659"},{"key":"2026092908102872000_13.2.e002043.21","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1093\/rheumatology\/keaf027","article-title":"Distinct genetic risk loci between biopsy-proven renal and non-renal lupus: a 10-year longitudinal cohort","volume":"64","author":"Chan","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026092908102872000_13.2.e002043.22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11926-023-01109-6","article-title":"Flares in Lupus Nephritis: Risk Factors and Strategies for Their Prevention","volume":"25","author":"Banos","year":"2023","journal-title":"Curr Rheumatol Rep"},{"key":"2026092908102872000_13.2.e002043.23","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.143654","article-title":"A longitudinal and transancestral analysis of DNA methylation patterns and disease activity in lupus patients","volume":"5","author":"Coit","year":"2020","journal-title":"JCI Insight"},{"key":"2026092908102872000_13.2.e002043.24","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/art.42237","article-title":"Dynamics of Methylation of CpG Sites Associated With Systemic Lupus Erythematosus Subtypes in a Longitudinal Cohort","volume":"74","author":"Lanata","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026092908102872000_13.2.e002043.25","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-024-01792-x","article-title":"Changes in DNA methylation are associated with systemic lupus erythematosus flare remission and clinical subtypes","volume":"16","author":"Horton","year":"2024","journal-title":"Clin Epigenetics"},{"key":"2026092908102872000_13.2.e002043.26","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005050","article-title":"Transcriptome analysis to decipher the molecular underpinnings of response to treatment in systemic lupus erythematosus","volume":"11","author":"Garantziotis","year":"2025","journal-title":"RMD Open"},{"key":"2026092908102872000_13.2.e002043.27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151696","article-title":"Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide","volume":"11","author":"Audemard-Verger","year":"2016","journal-title":"PLoS One"},{"key":"2026092908102872000_13.2.e002043.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02690.x"},{"key":"2026092908102872000_13.2.e002043.29","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150665"},{"key":"2026092908102872000_13.2.e002043.30","first-page":"651","article-title":"Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity","volume":"32","author":"Weinshilboum","year":"1980","journal-title":"Am J Hum Genet"},{"key":"2026092908102872000_13.2.e002043.31","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-013-2583-6"},{"key":"2026092908102872000_13.2.e002043.32","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-024-01699-7","article-title":"DNA methylation and whole-genome transcription analysis in CD4+ T cells from systemic lupus erythematosus patients with or without renal damage","volume":"16","author":"Liu","year":"2024","journal-title":"Clin Epigenetics"},{"key":"2026092908102872000_13.2.e002043.33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2478\/jtim-2024-0013","article-title":"Recognition of differently expressed genes and DNA methylation markers in patients with Lupus nephritis","volume":"12","author":"Liu","year":"2024","journal-title":"J Transl Int Med"},{"key":"2026092908102872000_13.2.e002043.34","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70453","article-title":"Applying Genetic Risk Score to Improve Risk Assessment of New-Onset Lupus Nephritis in Systemic Lupus Erythematosus: A Large-Scale Prospective Cohort Study","volume":"6","author":"Ding","year":"2025","journal-title":"MedComm (2020)"},{"key":"2026092908102872000_13.2.e002043.35","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.067835"},{"key":"2026092908102872000_13.2.e002043.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2013.07.001"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2026-002043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:15:17Z","timestamp":1790694917000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2026-002043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,9,1]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/lupus-2026-002043"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2026-002043","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}